These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
761 related articles for article (PubMed ID: 28086946)
1. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496 [TBL] [Abstract][Full Text] [Related]
3. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Hu Y; Xu K; Yagüe E Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794 [TBL] [Abstract][Full Text] [Related]
4. The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer. Li Y; Deng H; Lv L; Zhang C; Qian L; Xiao J; Zhao W; Liu Q; Zhang D; Wang Y; Yan J; Zhang H; He Y; Zhu J Oncotarget; 2015 Apr; 6(12):10195-206. PubMed ID: 25991669 [TBL] [Abstract][Full Text] [Related]
5. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5. Cao Y; Chen J; Wang D; Peng H; Tan X; Xiong D; Huang A; Tang H Oncotarget; 2015 Nov; 6(35):38093-106. PubMed ID: 26497554 [TBL] [Abstract][Full Text] [Related]
6. ING5 suppresses breast cancer progression and is regulated by miR-24. Cui S; Liao X; Ye C; Yin X; Liu M; Hong Y; Yu M; Liu Y; Liang H; Zhang CY; Chen X Mol Cancer; 2017 May; 16(1):89. PubMed ID: 28490335 [TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. Zhang X; Huang L; Zhao Y; Tan W Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis. Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1. Wu DD; Li XS; Meng XN; Yan J; Zong ZH Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917 [TBL] [Abstract][Full Text] [Related]
11. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving. Wang DY; Li N; Cui YL Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583 [TBL] [Abstract][Full Text] [Related]
12. miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). Ye J; Zhang Z; Sun L; Fang Y; Xu X; Zhou G Mol Biosyst; 2016 Oct; 12(11):3417-3424. PubMed ID: 27714074 [TBL] [Abstract][Full Text] [Related]
13. ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression. Gou WF; Shen DF; Yang XF; Zhao S; Liu YP; Sun HZ; Su RJ; Luo JS; Zheng HC Oncotarget; 2015 Aug; 6(23):19552-79. PubMed ID: 25980581 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092 [TBL] [Abstract][Full Text] [Related]
15. The down-regulated ING5 expression in lung cancer: a potential target of gene therapy. Zhao S; Yang XF; Shen DF; Gao Y; Shi S; Wu JC; Liu HX; Sun HZ; Su RJ; Zheng HC Oncotarget; 2016 Aug; 7(34):54596-54615. PubMed ID: 27409347 [TBL] [Abstract][Full Text] [Related]
16. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637 [TBL] [Abstract][Full Text] [Related]
17. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma. Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689 [TBL] [Abstract][Full Text] [Related]
18. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1. Liu Y; Niu Z; Lin X; Tian Y Cancer Gene Ther; 2017 May; 24(5):208-214. PubMed ID: 28281524 [TBL] [Abstract][Full Text] [Related]
19. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells. Shuang T; Wang M; Shi C; Zhou Y; Wang D FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097 [TBL] [Abstract][Full Text] [Related]
20. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response. Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]